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Abstract: With improved healthcare, the Down syndrome (DS) population is both growing and
aging rapidly. However, with longevity comes a very high risk of Alzheimer’s disease (AD). The
LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting 270 adults with
DS over the age of 25. The study is designed to characterize trajectories of change in DS-associated
AD (DS-AD). The current study reports its cross-sectional analysis of the first 90 subjects enrolled.
Plasma biomarkers phosphorylated tau protein (p-tau), neurofilament light chain (NfL), amyloid β
peptides (Aβ1-40, Aβ1-42), and glial fibrillary acidic protein (GFAP) were undertaken with previously
published methods. The clinical data from the baseline visit include demographics as well as the
cognitive measures under the Severe Impairment Battery (SIB) and Down Syndrome Mental Status
Examination (DS-MSE). Biomarker distributions are described with strong statistical associations
observed with participant age. The biomarker data contributes to understanding DS-AD across the
spectrum of disease. Collectively, the biomarker data show evidence of DS-AD progression beginning
at approximately 40 years of age. Exploring these data across the full LIFE-DSR longitudinal study
population will be an important resource in understanding the onset, progression, and clinical profiles
of DS-AD pathophysiology.
Keywords: Down syndrome; Alzheimer’s disease; blood biomarkers; phosphorylated tau protein;
amyloid β peptide; neurofilament light chain; glial fibrillary acidic protein
1. Introduction
With improved healthcare, the Down syndrome (DS) population is experiencing a
rapid increase in longevity with a life expectancy of >55 years of age compared to just
25 years of age in the 1980s. It is estimated that there are 210,000 people in the United
States and about 417,000 people in Europe living with DS. Furthermore, about 40% of the
DS population in the United States is over the age of 30 years [1,2]. However, with this
change in longevity comes a very high risk of Alzheimer’s disease (AD). It is estimated
that the lifetime risk of AD is >90% [3], and it is the leading cause of death for adults with
DS [4]. DS-associated AD (DS-AD) is a slow, progressive disease associated with many of
the same symptoms commonly seen in sporadic AD such as cognitive decline, behavioral
issues, and functional decline impacting activities of daily living [5,6].
Early-onset AD (EOAD) is defined as those who present with clinical signs of AD
before the age of 65. People with EOAD represent only about 5% or less of the 5.8 million
AD cases in the United States [7] and 50 million globally [8]. A well-studied sub-set of the
EOAD population are those with a known autosomal dominant AD (AD-AD) mutation
in amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) [9–11].
Individuals with DS represent the largest group of individuals with EOAD with a median
age of diagnosis of AD dementia of approximately 55 years [12]. Yet people with DS
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remain under-studied and are often not included in the investigations seeking to generate
prevalence estimates of EOAD.
DS-AD is likely driven by genetics through a gene-dose effect of APP, which is located
on chromosome 21 and is overexpressed in DS [13]. Furthermore, DS-AD biomarkers
follow an order of change like sporadic AD, progressing over 10–20 years before the
onset of cognitive decline [14]. By their 40s, the vast majority of adults with DS develop
neuropathology consistent with AD [15], while individuals with DS and partial trisomy
21 results in 2 copies of the APP gene serving as a notable exception. The latter support
the hypothesis that an extra copy of the APP gene contributes to the risk of AD in people
with DS [16]. There are other factors that might impact the age of onset. For example, there
is evidence that people with DS who carry apolipoprotein E (APOE) ε4 exhibit increased
risk of earlier symptom onset and an increased amyloid load [17]. There could be other
risk factors including co-morbid disorders such as obesity or untreated sleep apnea, that
may also contribute to an earlier age of onset, but more research is needed to clarify their
potential role.
The neuropathology of DS-AD is known to be very similar to that found in spo-
radic or late-onset AD (LOAD) and AD-AD. A widely supported model for sporadic
and autosomal dominant AD consists of early amyloid β (Aβ) deposition, followed by
hyperphosphorylated tau protein (p-tau) accumulation that is subsequently followed by
neurodegeneration [18]. In this model, a long preclinical phase with the presence of AD
pathology, specifically Aβ deposition, occurs more than 15 years before an individual
develops overt cognitive symptoms. With the characterization of amyloid biomarkers
(A), tau biomarkers (T), and neurodegeneration markers (N), it is now possible to apply
both the AT(N) framework [19] and the biologically based research diagnostic criteria for
Alzheimer’s disease [20]. This predominant model for LOAD and AD-AD was recently
adapted to DS-AD [21,22]. Support for this model in DS-AD was seen in a recent study of
a cross-sectional examination of a large cohort of adults with DS. The data from the study
showed that DS-AD follows a similar trajectory of changes to that described in AD-AD. The
study assessed multiple AD biomarkers (including samples from blood and cerebrospinal
fluid (CSF), positron emission tomography (PET), magnetic resonance imaging (MRI), and
cognitive tests) in 388 participants with DS. Data showed that biomarkers reflecting AD
pathogenesis in individuals with DS behave similarly to AD biomarkers in individuals
with LOAD and AD-AD [23,24].
The utility of fluid biomarkers to define the stage and progression in DS-AD is emerg-
ing. Recent data from the multi-site Alzheimer’s Biomarker Consortium–Down Syndrome
(ABC-DS) cohort (n = 44) showed that the CSF AD biomarker profiles are very similar
to LOAD and AD-AD [25]. The study showed that individuals with AD dementia had
low CSF Aβ1–42 and Aβ42/Aβ40 ratio, indicative of amyloid deposition; increased p-tau,
denoting the presence of neurofibrillary tangles [26–28]; and increased total tau and neuro-
filament light chain (NfL), indicating neurodegeneration [25]. The ABC-DS study findings
are consistent with the results from the Down Alzheimer Barcelona Neuroimaging Initiative
(DABNI) cohort in Europe [29]. Taken together, there is directional support for this revised
AD diagnostic framework being potentially applicable and valuable in DS, with further
need to characterize the sequencing and evolution of these biomarkers in DS from the
asymptomatic through dementia stages [19,20]. The arrival of plasma biomarkers, which
mirror CSF, and PET imaging measures provides a very attractive and more applicable less
invasive fluid biomarker.
Data from the DABNI study and the LonDownS (London Down Syndrome) Con-
sortium both point to NfL as a prognostic biomarker [29,30]. CSF Aβ42/Aβ40 ratio and
plasma NfL were the first biomarkers to show changes at 28–30 years of age [23]. Use of
NfL as a biomarker of LOAD has been problematic as it is a general marker of neurode-
generation and is itself correlated with age. Because people with LOAD are older than 65
and often show evidence of multiple comorbidities, the interpretation of increased NfL
can be difficult. In fact, there is evidence that multiple pathologies are present together
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with those characteristics of AD in approximately 66% of the LOAD population. Given
that aging is associated with presence of several neurodegenerative and non-degenerative
diseases that also increase NfL levels, the increases in NfL cannot be attributed specifically
to AD [31]. In contrast, EOAD populations, such as DS-AD, are much less likely to har-
bor other degenerative disorders. Thus, in EOAD, NfL can be used to more confidently
define the onset of AD. In fact, emerging data indicate that plasma NfL could be useful
as a prognostic biomarker in the unique DS-AD population [32]. Glial fibrillary acidic
protein (GFAP) is an intermediate filament protein found in the astroglial cytoskeleton and
is another emerging marker of neurodegeneration. GFAP expression is key to astrocyte
function and is upregulated in neurodegenerative diseases such as AD [33]. However,
more research is needed on the use of plasma GFAP as a biomarker of DS-AD progression.
It appears that our study is the first report of plasma GFAP data from DS individuals
in the literature. A recent study with samples from three different cohorts that included
LOAD and AD-AD participants showed that plasma p-tau 217 can distinguish AD from
other neurodegenerative diseases [34]. The use of plasma p-tau 217 in DS may have some
specificity in being able to further define the progression and clinical diagnosis of DS-AD.
Given the strong genetic risk of AD in DS and the biomarker evidence of a temporal
sequence of pathology similar to that in LOAD, a close exploration of the natural history of
DS-AD should enrich our understanding of all forms of AD and enhance knowledge of
potential biomarkers and outcome measures for therapeutic interventional studies. The
LIFE-DSR study [35] is a longitudinal natural history study recruiting 270 adults with
DS over the age of 25. The LIFE-DSR study has been designed to better understand
the factors that underlie symptoms, progression, and age-related changes in the clinical
presentation of DS-AD. Its design aims at characterizing trajectories of change in DS-AD at
3 visits across 32 months (baseline, month 16, and month 32) and collects sociodemographic
characteristics, medical history, physical exam, neuropsychiatric evaluation (not reported
here), cognitive status assessments, and a blood draw for AD biomarkers including APOE
ε4 analyses.
2. Experimental Section
Enrollment in the study started at the end of 2019. Paused in 2020 due to the COVID-19
pandemic, an opportunity was provided to conduct an exploratory analysis of the first 90
banked plasma samples to assess the cross-sectional distribution of baseline AD biomarkers
p-tau 181, p-tau 217, NfL, Aβ1-40, Aβ1-42, and GFAP. Statistical associations between clinical
measures, sociodemographic characteristics, and biomarkers were evaluated.
2.1. Cognitive Assessments
The Severe Impairment Battery (SIB) [36] assesses the skills of people with severe
dementia utilizing 40 simple one-step commands and gestural cues, presented in a relatively
naturalistic, conversational style. There are six subscales: attention, orientation, language,
memory, visuospatial ability, and construction. Assessment of praxis, social interaction,
and orientation to name is also included. The maximum score is 100, with higher score
indicating less impairment.
Down Syndrome Mental Status Examination (DS-MSE) is a neuropsychological test
battery measuring a broad range of skills including recall of personal information, orienta-
tion to season and day of the week, short-term memory, language, visuospatial construction,
and praxis [37]. The maximum score is 87 using scoring method 2, with a higher score
indicating less impairment [38].
2.2. Genetic Assays
Apolipoprotein E (APOE)
APOE genotypes for rs7412 and rs429358 were assayed from LIFE-DSR participant
DNA by the National Centralized Repository for Alzheimer’s Disease and Related Demen-
tias (NCRAD) to generate APOE ε2/ε3/ε4 alleles. Genotyping was done using a customized
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96-SNP chip with the Fluidigm microfluidics-based DNA fingerprinting, from DNA sam-
ples banked at NCRAD. Fingerprint data were evaluated for call rate, heterozygosity ratio,
subject sex, and concordance with any other available samples; only samples passing all
quality control were used to generate APOE genotypes.
2.3. Biomarker Assays
2.3.1. Plasma P-tau Assays
Both p-tau181 and p-tau217 levels were measured in duplicate by electrochemilumi-
nescence using a proprietary assay developed by Lilly Research Laboratories as previously
described [25–27,34,39–41]. Briefly, samples were diluted 1:2 and 50 µL of diluted sample
was used for each replicate. The assay was performed on a streptavidin small spot plate
using the Meso Scale Discovery platform. P-tau181 used Biotinylated-AT270 (mIgG1)
as the capture, and p-tau217 used Biotinylated-IBA493 (mIgG1) as the capture. In this
study, both assays used SULFO-4G10-E2 (anti-tau monoclonal antibody developed by Lilly
Research Laboratories) as the detector. Each assay was calibrated using a unique synthetic
p-tau peptide.
2.3.2. NfL and 4-Plex Assays
Quanterix Simoa NfL and Neurology 4-Plex E (NfL, Aβ1-40, Aβ1-42, and GFAP) assays
were allowed to equilibrate to room temperature before use. Plasma samples were thawed
on wet ice and briefly vortexed prior to dilution and spun at 2000× g for 10 min at 4C.
Prediluted calibrators were also thawed on wet ice prior to use along with provided control
samples. Plasma samples as well as controls were diluted 1:4 in the provided sample
diluent. Further, 200 µL of all calibrators, control samples, and plasma samples were
loaded onto a 450 µL v-bottom plate and loaded onto the Simoa HD-X along with kit
provided SBG, beads, detector, and RGP. Each assay was run according to the manufacturer
assay definitions. Since NfL results were available from both single and multiplex assays
and the correlation coefficient was very high (R2 = 0.92), single plex Simoa NfL data were
used in all analyses [32].
2.4. Statistical Analyses
Spearman rank-based correlations were used to test monotonic associations between
biomarker and clinical variables. Associations between biomarkers and age were further
investigated using linear regression with restricted cubic spline fits on raw or z-transformed
scales and Huber–White robust standard errors. A secondary analysis of the association
between biomarkers and age considered APOE ε4 carrier status and sex as additive co-
variates. An alpha of 5% was used for statistical significance unless otherwise noted.
Confidence intervals (CI) are 95% CIs. Data management, graphics, and statistical anal-
yses were performed using Stata v16.1 and R v4.0.3 software (including tidyverse and
psych packages).
3. Results
Among the first 90 LIFE-DSR study participants with plasma samples accessible for
analysis, where demographics were available, the mean age was 38.3 years, and 46.5%
were women. Baseline demographics, plasma biomarker values, and cognitive assessment
scores are summarized in Table 1. Despite the relatively young age of the participants,
age was strongly correlated with biomarker levels as illustrated in Figure 1. Decline in the
Aβ42/Aβ40 ratio was observed starting with participants at about 45 years of age indicative
of the formation of amyloid plaques.
J. Clin. Med. 2021, 10, 1907 6 of 11
Table 1. Demographics and baseline biomarkers for first 90 subjects in Longitudinal Investigation for Enhancing Down
Syndrome Research (LIFE-DSR) Study.
Characteristic Mean (SD) Median (Q1, Q3) Min, Max N (%)
p-tau 217 pg/mL 0.26 (0.38) 0.14 (0.08, 0.25) 0.01, 2.72 90 (100.00%)
p-tau 181 pg/mL 1.22 (1.10) 0.81 (0.59, 1.45) 0.37, 7.40 90 (100.00%)
NfL pg/mL 13.84 (7.19) 11.90 (9.28, 18.06) 5.13, 46.87 90 (100.00%)
GFAP pg/mL 100.37 (57.02) 84.74 (63.44, 123.65) 36.19, 445.03 90 (100.00%)
Aβ1-40 pg/mL 210.03 (52.36) 215.82 (188.07, 234.87) 66.32, 417.74 90 (100.00%)
Aβ1-42 pg/mL 8.81 (2.42) 8.90 (7.36, 10.24) 2.22, 13.82 90 (100.00%)
Aβ42/Aβ40 ratio 0.04 (0.01) 0.04 (0.04, 0.05) 0.01, 0.06 90 (100.00%)
DS-MSE Total Score 2 64.23 (11.25) 65.00 (59.00, 72.00) 30.00, 82.00 79 (87.78%)
SIB Total Score 87.92 (14.04) 93.00 (86.00, 96.50) 14.00, 100.00 84 (93.33%)
Age (years) 38.31 (9.47) 37.00 (30.00, 45.00) 25.00, 69.00 86 (95.56%)
Female Male
Gender 40 (46.51%) 46 (53.49%)
Non-Carrier Carrier
APOE ε4 67 (74.44%) 23 (25.56%)
Aβ1-40 = amyloid β peptide 1-40, Aβ1-42 = amyloid β peptide 1-42, APOE ε4 = apolipoprotein E ε4 allele, DS-MSE = Down Syndrome
Mental Status Examination, GFAP = glial fibrillary acidic protein, Min = minimum, Max = maximum, N = number, NfL = neurofilament
light, pg/mL = picogram/milliliter, p-tau 181 = phosphorylated tau at threonine-181, p-tau 217 = phosphorylated tau at threonine − 217,
Q1 = quartile 1, Q3 = quartile 3, SD = standard deviation, SIB = Severe Impairment Battery.




Figure 1. Shown are the predictions from linear regressions of each biomarker on age, using re-
stricted cubic splines with 4 knots. Biomarkers were z-transformed to standardize the Y-axis. Robust 
standard errors were used. F-tests for the association of each biomarker with age was statistically 
significant (GFAP: F(3, 82) = 14.05, p < 0.0001; p-tau 217: F(3, 82) = 9.91, p < 0.0001; p-tau 181: F(3, 82) 
= 10.14, p < 0.0001; NfL: F(3, 82) = 34.57, p < 0.0001; Aβ42/Aβ40 ratio: F(3, 82) = 4.71, p = 0.0044), but for 
the Aβ42/Aβ40 ratio, this is dependent on the oldest participant; see Supplementary Figure S2, Figure 
S3, Figure S4, Figure S5, and Figure S6. (Abbreviations: Aβ42/40 = amyloid β42/40 ratio, GFAP = glial 
fibrillary acidic protein, NfL = neurofilament light, p-tau 181 = phosphorylated tau at threonine−181, 
p-tau 217 = phosphorylated tau at threonine−217). 
Spearman correlations between age, plasma biomarker values, and SIB and DS-MSE 
scores are summarized in Supplementary Figure S1. Baseline SIB and DS-MSE scores were 
positively correlated with each other. 
Inter-plasma biomarker correlations provide further insight into the progression of 
DS-AD. As expected, Aβ42/40 ratio was negatively correlated with NfL and p-tau181 and 
strong correlations were seen between p-tau217 and p-tau181. The strong correlations 
seen between NfL and p-tau217 or p-tau181, respectively, and GFAP and p-tau217 or p-
tau181 are similar to previous studies in LOAD where the order of biomarker changes has 
been investigated [42]. Spearman correlations with scatter plots are illustrated in Supple-
mentary Figure S1. All statistically significant correlations remained after test multiplicity 
correction by Bonferroni’s method, except the weaker associations between Aβ42/Aβ40 and 
NfL or p-tau181. 
4. Discussion 
Plasma protein biomarkers provide an accessible tool for elucidating the molecular 
processes active in DS-AD. These emerging biomarkers may be useful for prognosis and 
diagnosis in DS-AD. In our interim analysis, we evaluated AD biomarkers of APP metab-
olism (Aβ1-40 and Aβ1-42), tau tangle pathology (p-tau 181 and p-tau 217), and neurodegen-
eration (NfL, GFAP) at a single timepoint and showed a strong association with age. These 
three classes of plasma biomarkers correspond with the AT(N) research framework to de-
fine AD [20]. From the modelling undertaken, the amyloid (A) biomarker measure of Aβ1-
42/Aβ1-40 appears to change earliest with an initial increase in ratio followed inflection point 
in the mid-1940s and then progressive lowering thereafter. The tau (T) biomarkers both 
p-181 and p-217 tau have a progressively upwards trajectory that becomes apparent in the 
Figure 1. Shown are the predictions from linear regressions of each biomarker on age, using restricted cubic splines
with 4 knots. Biomarkers were z-transformed to standardize the Y-axis. Robust standard errors were used. F-tests
for the association of each biomarker with age was statistically significant (GFAP: F(3, 82) = 14.05, p < 0.0001; p-tau
217: F(3, 82) = 9.91, p < 0.0001; p-tau 181: F(3, 82) = 10.14, p < 0.0001; NfL: F(3, 82) = 34.57, p < 0.0001; Aβ42/Aβ40 ratio:
F(3, 82) = 4.71, p = 0.0044), but for the Aβ42/Aβ40 ratio, this is dependent on the oldest participant; see Supplementary
Figures S2–S6. (Abbreviations: Aβ42/40 = amyloid β42/40 ratio, GFAP = glial fibrillary acidic protein, NfL = neurofilament
light, p-tau 181 = phosphorylated tau at threonine−181, p-tau 217 = phosphorylated tau at threonine−217).
As indicated in Figure 1, NfL values increased steadily with increasing age. In contrast,
GFAP, p-tau217, and p-tau181 values were stable until the late forties at which point, they
also demonstrated increases with age. Non-standardized restricted cubic spline fits for
the plasma biomarkers are illustrated in Supplementary Figures S2–S6. The significant
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associations with age for p-tau, NfL, and GFAP were found to be robust after adjusting for
APOE ε4 carrier status and sex (Supplementary Figure S7). The increase in p-tau181 and of
p-tau217 by age 40 is evidence for hyperphosphorylated tau protein 10–15 years before the
average age of symptom onset.
Spearman correlations between age, plasma biomarker values, and SIB and DS-MSE
scores are summarized in Supplementary Figure S1. Baseline SIB and DS-MSE scores were
positively correlated with each other.
Inter-plasma biomarker correlations provide further insight into the progression of
DS-AD. As expected, Aβ42/40 ratio was negatively correlated with NfL and p-tau181 and
strong correlations were seen between p-tau217 and p-tau181. The strong correlations seen
between NfL and p-tau217 or p-tau181, respectively, and GFAP and p-tau217 or p-tau181
are similar to previous studies in LOAD where the order of biomarker changes has been
investigated [42]. Spearman correlations with scatter plots are illustrated in Supplementary
Figure S1. All statistically significant correlations remained after test multiplicity correction
by Bonferroni’s method, except the weaker associations between Aβ42/Aβ40 and NfL
or p-tau181.
4. Discussion
Plasma protein biomarkers provide an accessible tool for elucidating the molecu-
lar processes active in DS-AD. These emerging biomarkers may be useful for prognosis
and diagnosis in DS-AD. In our interim analysis, we evaluated AD biomarkers of APP
metabolism (Aβ1-40 and Aβ1-42), tau tangle pathology (p-tau 181 and p-tau 217), and neu-
rodegeneration (NfL, GFAP) at a single timepoint and showed a strong association with age.
These three classes of plasma biomarkers correspond with the AT(N) research framework
to define AD [20]. From the modelling undertaken, the amyloid (A) biomarker measure of
Aβ1-42/Aβ1-40 appears to change earliest with an initial increase in ratio followed inflection
point in the mid-1940s and then progressive lowering thereafter. The tau (T) biomarkers
both p-181 and p-217 tau have a progressively upwards trajectory that becomes apparent
in the early to mid-1940s, while the neurodegenerative biomarkers of GFAP and NfL are
also both informative. The NfL levels appear to increase progressively from the mid-1920s,
while GFAP has its upward inflection point from the mid-1940s. In the initial AT(N) pro-
posal, these neurodegenerative biomarkers were not included, however, their potential
utility in DS was appreciated. The steady increase in NfL with increasing age may be
particularly useful for assessing overall disease progression [32]. Overall, we searched for
correlations between biomarkers and with age, APOE ε4 status and clinical assessments of
cognition and function. As highlighted above, this interim analysis of plasma biomarkers
showed a strong age association.
The use of plasma protein biomarkers, while encouraging, may have limitations. For
example, the CSF Aβ42/Aβ40 ratio shows an initial decline at 28–30 years of age in DS [23].
Furthermore, evidence of amyloid deposition in people around the age of 30 is consistent
with previous studies of DS brain pathology [15]. Why the Aβ42/Aβ40 measures in the
CSF and plasma differ is not clear; however, one speculation is that the recently created
plasma Aβ1-40 and Aβ1-42 assays lack sensitivity to detect Aβ deposition in people with
DS before the age of 45.
Correlations were not observed between either the SIB or DS-MSE and the plasma
biomarkers. This may be due to wide variability in cognition and function in people with
DS. It may also speak to the need for more sensitive assessments designed specifically
for DS-AD and validated for use in longitudinal studies. A recent longitudinal study
showed an association with amyloid positron emission tomography (PET) imaging with
cognitive decline as measured by the Cued Recall Test [43]. In addition, a novel composite
scale has been developed with longitudinal data from multiple sites which also has the
potential to detect early stages of DS-AD [44]. The LIFE-DSR study also plans to collect
longitudinal cognitive and functional data and blood samples at 16 and 32 months with
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the hope of observing associations between plasma biomarker progression and cognitive
and functional decline.
Our interim analysis has provided valuable data on the use of plasma biomarkers
to help characterize DS-AD. While the number of participants was modest (n = 90) and
the mean age is relatively young (38.3 years), the modeling of the biomarkers provides
useful insights into the potential evolution of DS-AD. Remarkably, given that our analysis
was cross-sectional, the biomarkers were exceptionally well behaved. They suggest that
age alone predicts biomarker status and, therefore, the state of AD progression. Taken
together, biomarker data are evidence that progression of DS-AD begins no later than the
early forties i.e., 10–15 years before dementia is diagnosed. The next steps for the LIFE-DSR
study include increasing the number of participants to 270 and gathering longitudinal data
at 16 and 32 months. Longitudinal data from 270 participants should provide even greater
insights into the progression of DS-AD and in so doing set the stage for clinical trials of
potentially effective treatments for DS-AD and possibly for all forms of AD.
5. Patents
Subject matter relating to the assays, methods, reagents and/or compositions of matter
set forth herein are subject to patents and/or patent applications of Eli Lilly and Company.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jcm10091907/s1, Figure S1: Histograms (diagonal), scatterplots (below diagonal), and
Spearman correlations (above diagonal) for biomarkers and clinical data; Figure S2: Linear regression
fit of untransformed GFAP on age, using restricted cubic splines with 4 knots and robust standard
errors; Figure S3: Linear regression fit of untransformed p-tau 217 on age, using restricted cubic
splines with 4 knots and robust standard errors; Figure S4: Linear regression fit of untransformed
p-tau 181 on age, using restricted cubic splines with 4 knots and robust standard errors; Figure S5:
Linear regression fit of untransformed NfL on age, using restricted cubic splines with 4 knots and
robust standard errors; Figure S6: Linear regression fit of untransformed Aβ42/Aβ40 ratio on age,
using restricted cubic splines with 4 knots and robust standard errors; Figure S7: Shown are the
predictions from linear regressions of each biomarker on age, using restricted cubic splines with 4
knots, and adjusted for APOE e4 carrier status and sex using additive covariates; APOE e4 adjusted
to non-carrier and sex adjusted to female.
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